Related references
Note: Only part of the references are listed.Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
D. L. Roberts et al.
BRITISH JOURNAL OF CANCER (2009)
VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection
K. Engels et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Blocking neuropilin-2 function inhibits tumor cell metastasis
Maresa Caunt et al.
CANCER CELL (2008)
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
Duyen T. Dang et al.
CANCER RESEARCH (2008)
Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies?
Timothy J. Duncan et al.
CLINICAL CANCER RESEARCH (2008)
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer:: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy
Aristotelis Bamias et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in the treatment of ovarian cancer
Ernest S. Han et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential predictors of chemotherapy response in ovarian cancer - How do we define chemosensitivity?
S. A. O'Toole et al.
GYNECOLOGIC ONCOLOGY (2007)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
LM Hu et al.
CLINICAL CANCER RESEARCH (2005)
Immunohistochemical expression of vascular endothelial growth factor and microvessel counting as prognostic indicators in node-negative colorectal cancer
GM Boxer et al.
TUMOR BIOLOGY (2005)
Inhibition of the vascular-endothelial growth factor-induced intracellular signaling and mitogenesis of human endothelial cells by epigallocatechin-3 gallate
T Neuhaus et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma
MR Raspollini et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2004)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Share Paper
